šŸ“Š This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Evommune

1.1 - Company Overview

Evommune Logo

Evommune

Headquarter: United States
Founded: 20XXšŸ”’
Employees: 100-500šŸ”’
šŸŒ Website

Company description

  • Provider of therapeutics to halt progressive disease and address symptoms, focused on chronic inflammatory diseases. Develops EVO756, an oral, highly selective MRGPRX2 inhibitor for chronic spontaneous urticaria despite H1 antihistamines; a PKCĪø inhibitor to regulate immune response; collaborative drug discovery with partners like Accutar; and clinical trial programs, including Phase 1 for EVO756.

Products and services

  • EVO756: Orally administered, highly selective MRGPRX2 inhibitor being developed for chronic spontaneous urticaria patients remaining symptomatic despite H1 antihistamines, with Phase 1 studies assessing safety, tolerability, and efficacy
  • Clinical Trials: Phase 1ā€“oriented programs constructed to evaluate safety, tolerability, and efficacy of investigational therapies for chronic inflammatory diseases, including Phase 1 trials for EVO756
  • PKCĪø Inhibitor: Evommune engineers a small-molecule inhibitor targeting Protein Kinase C Theta (PKCĻ“) to regulate immune cell response, with potential applications across immune-mediated chronic inflammatory diseases

Key contacts

šŸ”’
šŸ”’

Financial details

šŸ”’

1.2 - Competitors and similar companies to Evommune

PureTech Health Logo

PureTech Health

HQ: United States Website
  • Description: Provider of biopharma therapies and platforms, including KarXT for schizophrenia (xanomeline + trospium), LYT-100 (deuterated pirfenidone) for idiopathic pulmonary fibrosis, LYT-200 (anti-galectin-9) for hematological malignancies and solid tumors, SPT-300 (oral allopregnanolone) for neurological and neuropsychiatric conditions, plus Vedanta's microbiome-based oral therapies and Entrega's hydrogel-enabled oral biologics.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ā—ā—ā—ā—ā—
  • Total funding raised: $ā—ā—ā—m
  • Backers: ā—ā—ā—ā—ā—ā—ā—ā—ā—ā—
  • Acquisitions: ā—ā—
View full PureTech Health company profile ā†’
Corbus Pharmaceuticals Logo

Corbus Pharmaceuticals

HQ: United States Website
  • Description: Provider of clinical-stage therapeutics targeting inflammatory and fibrotic diseases, with programs in oncology and obesity. Pipeline includes CRB-701, a next-generation Nectin-4-targeting ADC in trials for advanced solid tumors; CRB-601, an anti-integrin monoclonal antibody blocking TGFĪ² activation on cancer cells; and CRB-913, a peripherally restricted CB1 inverse agonist for obesity with IND planned.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ā—ā—ā—ā—ā—
  • Total funding raised: $ā—ā—ā—m
  • Backers: ā—ā—ā—ā—ā—ā—ā—ā—ā—ā—
  • Acquisitions: ā—ā—
View full Corbus Pharmaceuticals company profile ā†’
IMMCO Diagnostics Logo

IMMCO Diagnostics

HQ: United States Website
  • Description: Provider of innovative medical devices, diagnostic laboratory testing expertise, and pioneering research for a comprehensive solution to autoimmune disease diagnostics.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ā—ā—ā—ā—ā—
  • Total funding raised: $ā—ā—ā—m
  • Backers: ā—ā—ā—ā—ā—ā—ā—ā—ā—ā—
  • Acquisitions: ā—ā—
View full IMMCO Diagnostics company profile ā†’
Sitryx Logo

Sitryx

HQ: United Kingdom Website
  • Description: Provider of cell metabolismā€“targeted, first-in-class, disease-modifying therapeutics in immuno-oncology and immuno-inflammation. Pipeline includes SYX-5219 for atopic dermatitis; SIT-052, an inhaled GLS1 inhibitor for pulmonary fibrosis and COPD that selectively breaks down senescent cells; SIT-033, a SIK2 inhibitor for ulcerative colitis; and SYX-1042 and SIT-047 for autoimmune indications (with Eli Lilly).
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ā—ā—ā—ā—ā—
  • Total funding raised: $ā—ā—ā—m
  • Backers: ā—ā—ā—ā—ā—ā—ā—ā—ā—ā—
  • Acquisitions: ā—ā—
View full Sitryx company profile ā†’
Fresh Tracks Therapeutics Logo

Fresh Tracks Therapeutics

HQ: United States Website
  • Description: Provider of pharmaceutical therapeutics for autoimmune, inflammatory, and debilitating diseases.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ā—ā—ā—ā—ā—
  • Total funding raised: $ā—ā—ā—m
  • Backers: ā—ā—ā—ā—ā—ā—ā—ā—ā—ā—
  • Acquisitions: ā—ā—
View full Fresh Tracks Therapeutics company profile ā†’
šŸ”’

2.M&A buyers

2.1 Potential strategic acquirers in the sector

šŸ”’
šŸ”’
šŸ”’
šŸ”’ View all strategic buyers with complete profiles
Start Free Trial ā†’

2.2 - Strategic buyer groups for Evommune

šŸ”’

Buyer group 1: ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ

ā—ā— companies
Description: ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ
Key Products: ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ
šŸ”’ View all companies in this group
Request Free Trial Now ā†’
šŸ”’

Buyer group 2: ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ

ā—ā— companies
Description: ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ
Key Products: ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ
šŸ”’ View all companies in this group
Request Free Trial Now ā†’
šŸ”’

Buyer group 3: ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ

ā—ā— companies
Description: ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ
Key Products: ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ
šŸ”’ View all companies in this group
Request Free Trial Now ā†’
šŸ”“ Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial ā†’

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Evommune

2.2 - Growth funds investing in similar companies to Evommune

šŸ”’ View all growth equity funds with complete profiles
Start Free Trial ā†’

4 - Top valuation comps for Evommune

4.2 - Public trading comparable groups for Evommune

šŸ”“ Unlock all public trading comparable groups with complete valuation data
Start Free Trial ā†’

4.3 - M&A Transactions similar to Evommune

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
šŸ”’ View all M&A transactions with complete deal terms
Request Free Trial Now ā†’

Frequently Asked Questions

About Evommune

What does Evommune do?

Evommune is a provider of therapeutics to halt progressive disease and address symptoms, focused on chronic inflammatory diseases. Develops EVO756, an oral, highly selective MRGPRX2 inhibitor for chronic spontaneous urticaria despite H1 antihistamines; a PKCĪø inhibitor to regulate immune response; collaborative drug discovery with partners like Accutar; and clinical trial programs, including Phase 1 for EVO756.

Who are Evommune's competitors?

Evommune's competitors and similar companies include PureTech Health, Corbus Pharmaceuticals, IMMCO Diagnostics, Sitryx, and Fresh Tracks Therapeutics.

Where is Evommune headquartered?

Evommune is headquartered in United States.

How many employees does Evommune have?

Evommune has 1,000 employees šŸ”’.

When was Evommune founded?

Evommune was founded in 2010 šŸ”’.

What sector and industry vertical is Evommune in?

Evommune is in the Enterprise Software šŸ”’ sector and industry

M&A Buyers & Acquirers for Evommune

Who are the top strategic acquirers in Evommune's sector and industry

Top strategic M&A buyers and acquirers in Evommune's sector include ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, and ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ šŸ”’.

Which M&A buyer groups are most relevant for Evommune?

Top strategic M&A buyers groups and sectors for Evommune include ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ , ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, and ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ šŸ”’.

Financial Investors investing in Evommune's sector and industry vertical

Which are the top PE firms investing in Evommune's sector and industry vertical?

Top PE firms investing in Evommune's sector and industry vertical include ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, and ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ šŸ”’.

Who are the top buyout funds acquiring in Evommune's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Evommune's sector and industry vertical include ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, and ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ šŸ”’.

Who are the top growth equity funds investing in companies in Evommune's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Evommune include ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, and ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ šŸ”’.

Valuation benchmarks of companies in Evommune's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Evommune?

The key public trading comparables and valuation benchmarks for Evommune include ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, and ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ šŸ”’.

Which are the key trading comparable groups for Evommune for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Evommune with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Evommune's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Evommune with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Evommune's' sector and industry vertical?

Access recent funding rounds and capital raises in Evommune's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Evommune